Research progress of immune checkpoint inhibitors in the treatment of lung cancer

doi:10.3760/cma.j.cn371439-20201231-00135

Abstract

Abstract:

In recent years, immune checkpoint inhibitors are a milestone in the treatment of lung cancer. There are many kinds of immune checkpoints, which are closely related to the efficacy and drug resis-tance of immunotherapy, including programmed death-1 (PD-1), programmed death ligand-1 (PD-L1), cytotoxic T-lymphocyte antigen 4 (CTLA-4), killer cell immunoglobulin-like receptor (KIR), T cell immunoglobulin and ITIM domain (TIGIT), T-cell immunoglobulin and mucin domain-containing protein 3 (TIM-3), etc. PD-1/PD-L1 inhibitors have been approved by China National Medical Products Administration and U.S. Food and Drug Administration for the first-line treatment of lung cancer, which can improve overall survival and progression-free survival of patients. The double immunotherapies of CTLA-4 inhibitors or TIGIT inhibitors combined with PD-1/PD-L1 inhibitors also achieve good results, however, more serious adverse events may occur.The KIR and TIM-3 targets are closely related to the drug resistance of immunotherapy.

Key words: Immunotherapy, Lung neoplasms, Immune checkpoint inhibitors

Ma Jun, Zhang Hongying, Wu Aiping, Gao Guangyi. Research progress of immune checkpoint inhibitors in the treatment of lung cancer[J]. Journal of International Oncology, 2021, 48(11): 683-687.

References 38

[1]	Oberndorfer F, Müllauer L. Molecular pathology of lung cancer: current status and perspectives[J]. Curr Opin Oncol, 2018, 30(2):69-76. DOI: 10.1097/CCO.0000000000000429. doi: 10.1097/CCO.0000000000000429 pmid: 29251665
[2]	Ostoros G. Immunotherapy for lung cancer[J]. Magy Onkol, 2017, 61(2):153-157. pmid: 28585617
[3]	Jain P, Jain C, Vamsidhar V. Role of immune-checkpoint inhibitors in lung cancer[J]. Ther Adv Respir Dis, 2018, 12: 17534658177-50075. DOI: 10.1177/1753465817750075.
[4]	Reck M. Pembrolizumab as first-line therapy for metastatic non-small-cell lung cancer[J]. Immunotherapy, 2018, 10(2):93-105. DOI: 10.2217/imt-2017-0121. doi: 10.2217/imt-2017-0121
[5]	Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer[J]. N Engl J Med, 2016, 375(19):1823-1833. DOI: 10.1056/NEJMoa1606774. doi: 10.1056/NEJMoa1606774
[6]	Wu YL, Zhang L, Fan Y, et al. Randomized clinical trial of pembrolizumab vs chemotherapy for previously untreated Chinese patients with PD-L1-positive locally advanced or metastatic non-small-cell lung cancer: KEYNOTE-042 China study[J]. Int J Cancer, 2021, 148(9):2313-2320. DOI: 10.1002/ijc.33399. doi: 10.1002/ijc.v148.9
[7]	Gandhi L, Rodríguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer[J]. N Engl J Med, 2018, 378(22):2078-2092. DOI: 10.1056/NEJMoa1801005. doi: 10.1056/NEJMoa1801005
[8]	Paz-Ares L, Luft A, Vicente D, et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer[J]. N Engl J Med, 2018, 379(21):2040-2051. DOI: 10.1056/NEJMoa1810865. doi: 10.1056/NEJMoa1810865
[9]	Nosaki K, Saka H, Hosomi Y, et al. Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1-positive advanced NSCLC: pooled analysis from KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies[J]. Lung Cancer, 2019, 135:188-195. DOI: 10.1016/j.lungcan.2019.07.004. doi: 10.1016/j.lungcan.2019.07.004
[10]	Wu YL, Lu S, Cheng Y, et al. Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced NSCLC: CheckMate 078 randomized phase Ⅲ clinical trial[J]. J Thorac Oncol, 2019, 14(5):867-875. DOI: 10.1016/j.jtho.2019.01.006. doi: 10.1016/j.jtho.2019.01.006
[11]	Horn L, Spigel DR, Vokes EE, et al. Nivolumab versus docetaxel in previously treated patients with advanced non-small-cell lung cancer: two-year outcomes from two randomized, open-label, phase Ⅲ trials (CheckMate 017 and CheckMate 057)[J]. J Clin Oncol, 2017, 35(35):3924-3933. DOI: 10.1200/JCO.2017.74.3062. doi: 10.1200/JCO.2017.74.3062
[12]	Zhou C, Chen G, Huang Y, et al. Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial[J]. Lancet Respir Med, 2021, 9(3):305-314. DOI: 10.1016/S2213-2600(20)30365-9. doi: 10.1016/S2213-2600(20)30365-9
[13]	West H, McCleod M, Hussein M, et al. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial[J]. Lancet Oncol, 2019, 20(6):924-937. DOI: 10.1016/S1470-2045(19)30167-6. doi: 10.1016/S1470-2045(19)30167-6
[14]	Socinski MA, Jotte RM, Cappuzzo F, et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC[J]. N Engl J Med, 2018, 378(24):2288-2301. DOI: 10.1056/NEJMoa1716948. doi: 10.1056/NEJMoa1716948
[15]	Horn L, Mansfield AS, Szczęsna A, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer[J]. N Engl J Med, 2018, 379(23):2220-2229. DOI: 10.1056/NEJMoa1809064. doi: 10.1056/NEJMoa1809064
[16]	Paz-Ares L, Dvorkin M, Chen Y, et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial[J]. Lancet, 2019, 394(10212):1929-1939. DOI: 10.1016/S0140-6736(19)32222-6. doi: S0140-6736(19)32222-6 pmid: 31590988
[17]	Zhang H, Shen J, Yi L, et al. Efficacy and safety of ipilimumab plus chemotherapy for advanced lung cancer: a systematic review and meta-analysis[J]. J Cancer, 2018, 9(23):4556-4567. DOI: 10.7150/jca.27368. doi: 10.7150/jca.27368
[18]	Chae YK, Arya A, Iams W, et al. Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC)[J]. J Immunother Cancer, 2018, 6(1):39. DOI: 10.1186/s40425-018-0349-3. doi: 10.1186/s40425-018-0349-3
[19]	Pinto JA, Raez LE, Oliveres H, et al. Current knowledge of ipilimumab and its use in treating non-small cell lung cancer[J]. Expert Opin Biol Ther, 2019, 19(6):509-515. DOI: 10.1080/14712598.2019.1610380. doi: 10.1080/14712598.2019.1610380
[20]	Hellmann MD, Ciuleanu TE, Pluzanski A, et al. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden[J]. N Engl J Med, 2018, 378(22):2093-2104. DOI: 10.1056/NEJMoa1801946. doi: 10.1056/NEJMoa1801946
[21]	Ready NE, Ott PA, Hellmann MD, et al. Nivolumab monotherapy and nivolumab plus ipilimumab in recurrent small cell lung cancer: results from the CheckMate 032 randomized cohort[J]. J Thorac Oncol, 2020, 15(3):426-435. DOI: 10.1016/j.jtho.2019.10.004. doi: S1556-0864(19)33531-2 pmid: 31629915
[22]	Trefny MP, Rothschild SI, Uhlenbrock F, et al. A variant of a killer cell immunoglobulin-like receptor is associated with resistance to PD-1 blockade in lung cancer[J]. Clin Cancer Res, 2019, 25(10):3026-3034. DOI: 10.1158/1078-0432.CCR-18-3041. doi: 10.1158/1078-0432.CCR-18-3041
[23]	He Y, Liu S, Mattei J, Bunn PA Jr, et al. The combination of anti-KIR monoclonal antibodies with anti-PD-1/PD-L1 monoclonal antibodies could be a critical breakthrough in overcoming tumor immune escape in NSCLC[J]. Drug Des Devel Ther, 2018, 12:981-986.DOI: 10.2147/DDDT.S163304. doi: 10.2147/DDDT
[24]	Hu F, Wang W, Fang C, et al. TIGIT presents earlier expression dynamic than PD-1 in activated CD8⁺ T cells and is upregulated in non-small cell lung cancer patients[J]. Exp Cell Res, 2020, 396(1):112260. DOI: 10.1016/j.yexcr.2020.112260. doi: 10.1016/j.yexcr.2020.112260
[25]	Houssaini MS, Damou M, Ismaili N. Advances in the management of non-small cell lung cancer (NSCLC): a new practice changing data from ASCO 2020 annual meeting[J]. Cancer Treat Res Commun, 2020, 25:100239. DOI: 10.1016/j.ctarc.2020.100239. doi: 10.1016/j.ctarc.2020.100239 pmid: 33271494
[26]	Acharya N, Sabatos-Peyton C, Anderson AC. Tim-3 finds its place in the cancer immunotherapy landscape[J]. J Immunother Cancer, 2020, 8(1): e000911. DOI: 10.1136/jitc-2020-000911.
[27]	Jia K, He Y, Dziadziuszko R, et al. T cell immunoglobulin and mucin-domain containing-3 in non-small cell lung cancer[J]. Transl Lung Cancer Res, 2019, 8(6):895-906. DOI: 10.21037/tlcr.2019.11.17. doi: 10.21037/tlcr
[28]	Limagne E, Richard C, Thibaudin M, et al. Tim-3/galectin-9 pathway and mMDSC control primary and secondary resistances to PD-1 blockade in lung cancer patients[J]. Oncoimmunology, 2019, 8(4): e1564505. DOI: 10.1080/2162402X.2018.1564505.
[29]	Nowak EC, Lines JL, Varn FS, et al. Immunoregulatory functions of VISTA[J]. Immunol Rev, 2017, 276(1):66-79. DOI: 10.1111/imr.12525. doi: 10.1111/imr.2017.276.issue-1
[30]	Villarroel-Espindola F, Yu X, Datar I, et al. Spatially resolved and quantitative analysis of VISTA/PD-1H as a novel immunotherapy target in human non-small cell lung cancer[J]. Clin Cancer Res, 2018, 24(7):1562-1573. DOI: 10.1158/1078-0432.CCR-17-2542. doi: 10.1158/1078-0432.CCR-17-2542 pmid: 29203588
[31]	Hernandez-Martinez JM, Vergara E, Zatarain-Barrón ZL, et al. VISTA/PD-1H: a potential target for non-small cell lung cancer immunotherapy[J]. J Thorac Dis, 2018, 10(12):6378-6382. DOI: 10.21037/jtd.2018.11.39. doi: 10.21037/jtd.2018.11.39 pmid: 30746169
[32]	Datar I, Sanmamed MF, Wang J, et al. Expression analysis and significance of PD-1, LAG-3, and TIM-3 in human non-small cell lung cancer using spatially resolved and multiparametric single-cell analysis[J]. Clin Cancer Res, 2019, 25(15):4663-4673. DOI: 10.1158/1078-0432.CCR-18-4142. doi: 10.1158/1078-0432.CCR-18-4142 pmid: 31053602
[33]	Li X, Xu Z, Cui G, et al. BTLA expression in stage Ⅰ-Ⅲ non-small-cell lung cancer and its correlation with PD-1/PD-L1 and clinical outcomes[J]. Onco Targets Ther, 2020, 13:215-224. DOI: 10.2147/OTT.S232234. doi: 10.2147/OTT
[34]	Schoenfeld AJ, Rizvi H, Memon D, et al. Acquired resistance to PD-1 blockade in NSCLC[J]. J Clin Oncol, 2020, 38(15_suppl):9621. DOI: 10.1200/JCO.2020.38.15_suppl.9621. doi: 10.1200/JCO.2020.38.15_suppl.9621
[35]	Mok TSK, Wu YL, Kudaba I, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial[J]. Lancet, 2019, 393(10183):1819-1830. DOI: 10.1016/S0140-6736(18)32409-7. doi: 10.1016/S0140-6736(18)32409-7
[36]	Zhou C, Chen G, Huang Y, et al. A randomized phase 3 study of camrelizumab plus chemotherapy as 1st line therapy for advanced/metastatic non-squamous non-small cell lung cancer[J]. J Thorac Oncol, 2019, 14(10): S215-S216. DOI: 10.1016/j.jtho.2019.08.425.
[37]	Neal JW, Lim FL, Felip E, et al. Cabozantinib in combination with atezolizumab in non-small cell lung cancer (NSCLC) patients pre-viously treated with an immune checkpoint inhibitor: results from cohort 7 of the COSMIC-021 study[EB/OL]. [2020-11-12].https://meetinglibrary.asco.org/record/184892/abstract .
[38]	Grohé C, Blau W, Gleiber W, et al. Nintedanib + docetaxel in lung adenocarcinoma patients (pts) following treatment with immune checkpoint inhibitors (ICIs): updated efficacy and safety results of the ongoing non-interventional study (NIS) VARGADO (NCT02-392455) [EB/OL].[2020-11-12].https://meetinglibrary.asco.org/record/184885/abstract .